Alexey Danilov, MD, PhD, discusses some targeted therapies being investigated in the relapsed/refractory chronic lymphocytic leukemia space.
Alexey Danilov, MD, PhD, associate director, Toni Stephenson Lymphoma Center, and professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, discusses some targeted therapies being investigated in the relapsed/refractory chronic lymphocytic leukemia (CLL) space.
There are a number of targeted agents currently available for patients with CLL, including Bruton tyrosine kinase (BTK) inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, venetoclax (Venclexta), and more.
On top of these agents, there is a lot of early and encouraging data from newer studies. These trials are evaluating combination therapies, chimeric antigen receptor (CAR) T-cell therapies and pirtobrutinib (L0X0-305), a noncovalent BTK inhibitor.
Transcription:
0:08 | There are many studies going on now, which use the combination therapy of both BTK inhibitors and BCL-2 inhibitors, such as acalabrutinib [Calquence] and venetoclax or ibrutinib [Imbruvica] and venetoclax. The data from the studies are already emerging, and the early data is very encouraging. Those are time limited therapies in CLL.
0:32 | In addition, there are multiple other targeted agents being developed. For example, double refractory patients who have relapsed on both BTK inhibitors and the BCL-2 inhibitor venetoclax represent an unmet medical need now. Novel agents such as noncovalent BTK inhibitors like pirtobrutinib are being developed in that space. There are some novel BCL-2 inhibitors as well which are in clinical trials. BTK degraders, which have a slightly different mechanism where they don't just block the BTK, but lead to its degradation, are also In early phase clinical trials now with very limited data so far.
1:22 | In terms of immune or cell therapy approaches, there are some exciting data emerging with the CAR T-cell therapies which show efficacy in double refractory CLL as well, and here are several trials with bispecific antibodies, such as mosunetuzumab [Lunsumio], which also show early promise.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More